2139 related articles for article (PubMed ID: 23535601)
21. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Saqcena M; Mukhopadhyay S; Hosny C; Alhamed A; Chatterjee A; Foster DA
Oncogene; 2015 May; 34(20):2672-80. PubMed ID: 25023699
[TBL] [Abstract][Full Text] [Related]
22. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
23. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
[TBL] [Abstract][Full Text] [Related]
24. Glutamate-oxaloacetate transaminase activity promotes palmitate lipotoxicity in rat hepatocytes by enhancing anaplerosis and citric acid cycle flux.
Egnatchik RA; Leamy AK; Sacco SA; Cheah YE; Shiota M; Young JD
J Biol Chem; 2019 Mar; 294(9):3081-3090. PubMed ID: 30563841
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
Ying H; Kimmelman AC; Lyssiotis CA; Hua S; Chu GC; Fletcher-Sananikone E; Locasale JW; Son J; Zhang H; Coloff JL; Yan H; Wang W; Chen S; Viale A; Zheng H; Paik JH; Lim C; Guimaraes AR; Martin ES; Chang J; Hezel AF; Perry SR; Hu J; Gan B; Xiao Y; Asara JM; Weissleder R; Wang YA; Chin L; Cantley LC; DePinho RA
Cell; 2012 Apr; 149(3):656-70. PubMed ID: 22541435
[TBL] [Abstract][Full Text] [Related]
26. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract][Full Text] [Related]
27. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
[TBL] [Abstract][Full Text] [Related]
28. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
Keklikoglou I; Hosaka K; Bender C; Bott A; Koerner C; Mitra D; Will R; Woerner A; Muenstermann E; Wilhelm H; Cao Y; Wiemann S
Oncogene; 2015 Sep; 34(37):4867-78. PubMed ID: 25500542
[TBL] [Abstract][Full Text] [Related]
30. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
[TBL] [Abstract][Full Text] [Related]
31. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.
Yamamoto K; Tateishi K; Kudo Y; Sato T; Yamamoto S; Miyabayashi K; Matsusaka K; Asaoka Y; Ijichi H; Hirata Y; Otsuka M; Nakai Y; Isayama H; Ikenoue T; Kurokawa M; Fukayama M; Kokudo N; Omata M; Koike K
Carcinogenesis; 2014 Nov; 35(11):2404-14. PubMed ID: 24947179
[TBL] [Abstract][Full Text] [Related]
32. Eicosapentaenoic Acid Inhibits
Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
[TBL] [Abstract][Full Text] [Related]
33. Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition.
Jeong SM; Hwang S; Park K; Yang S; Seong RH
Sci Rep; 2016 Aug; 6():30767. PubMed ID: 27477484
[TBL] [Abstract][Full Text] [Related]
34. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance.
Lyssiotis CA; Son J; Cantley LC; Kimmelman AC
Cell Cycle; 2013 Jul; 12(13):1987-8. PubMed ID: 23759579
[No Abstract] [Full Text] [Related]
36. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
37. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
[TBL] [Abstract][Full Text] [Related]
38. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
39. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
Terado T; Kim CJ; Ushio A; Minami K; Tambe Y; Kageyama S; Kawauchi A; Tsunoda T; Shirasawa S; Tanaka H; Inoue H
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35894141
[TBL] [Abstract][Full Text] [Related]
40. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.
Ma Y; Gu Y; Zhang Q; Han Y; Yu S; Lu Z; Chen J
Mol Cancer Ther; 2013 Mar; 12(3):286-94. PubMed ID: 23288781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]